The Saudi Food and Drug Authority (SFDA) is the authority that oversees all drug manufacturing, trade, and registration in Saudi Arabia.
Saudi Arabian guidelines for biosimilars
Home/Guidelines
|
Posted 08/07/2011
0
Post your comment
The SFDA is in charge of licensing of the manufacture, import, export, distribution, promotion and advertising of medications, as well as assessing the safety, efficacy and quality of medications, and issuing marketing authorisations.
The SFDA also carries out inspections and surveillance of manufacturers, importers, wholesalers and dispensers of medicines; controls promotion and advertising of medicines; and provides independent information on medicines to professionals and the public.
In Saudi Arabia, final guidelines covering biosimilars were published by the SFDA in December 2010.
Overarching guideline
This guideline covers all biosimilar products:
Guidelines on biosimilars version 1.1
12 December 2010
www.sfda.gov.sa/NR/rdonlyres/CB28C6AF-79CD-4412-8801-35AEDEED0183/0/Guidelinesonbiosimilars_v11.pdf
The guideline also contains separate chapters on specific biosimilar products including insulin, interferons, erythropoietin, granulocyte colony stimulating factor and growth hormone.
Related article
Saudi Arabian guidelines for generics
Source: SFDA
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Related content
Regulatory update for post-registration of biological products in Brazil
Home/Guidelines Posted 29/10/2024
FDA interchangeable biosimilars guidance update on revised approach to switching studies
Home/Guidelines Posted 23/07/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment